Nektar Therapeutics Share Price Today: Live Updates & Key Insights

Nektar Therapeutics share price today is $72, up -3.5%. The stock opened at $75 against the previous close of $74.84, with an intraday high of $75.43 and low of $70.9.

Nektar Therapeutics Share Price Chart

Nektar Therapeutics

us-stock
To Invest in {{usstockname}}
us-stock

Nektar Therapeutics Share Price Performance

$72 -0.035(-3.5%) NKTR at 23 Mar 2026 02:28 PM Biotechnology
Lowest Today 70.9
Highest Today 75.43
Today’s Open 75
Prev. Close 74.84
52 Week High 77.00
52 Week Low 6.48
Day’s Range: Low 70.9 High 75.43
52-Week Range: Low 6.48 High 77.00
1 day return -
1 Week return +0.15
1 month return -1.69
3 month return +66.32
6 month return +22.51
1 year return +8345.27
3 year return +9154.99
5 year return +222.91
10 year return -

Nektar Therapeutics Institutional Holdings

Bvf Inc 5.57

Vanguard Group Inc 3.67

Morgan Stanley - Brokerage Accounts 3.32

Two Seas Capital LP 2.66

BlackRock Inc 2.18

Armistice Capital, LLC 2.13

Vanguard Total Stock Mkt Idx Inv 2.12

Prosight Management, LP 1.98

Two Sigma Investments LLC 1.69

Millennium Management LLC 1.62

Sofinnova Ventures 1.57

Emerald Advisers, LLC 1.37

Susquehanna International Group, LLP 1.37

22NW, LP 1.18

Qube Research & Technologies 1.16

Citadel Advisors Llc 1.11

Two Sigma Advisers, LLC 1.10

Jefferies Financial Group Inc 1.08

Great Point Partners LLC 1.07

VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.06

Balyasny Asset Management LLC 1.01

Vanguard Institutional Extnd Mkt Idx Tr 0.79

Invesco Main Street Small Cap R6 0.64

Invesco Small Cap Core 0.64

PRIMECAP Odyssey Aggressive Growth 0.64

BlackRock Global Equity Mkt Netrl Instl 0.50

Schwab US Small-Cap ETF™ 0.47

Fidelity Growth Compy Commingled Pl S 0.41

Fidelity Extended Market Index 0.38

State Street® SPDR® S&P® PhrmctlsETF 0.38

Emerald Growth A 0.37

Invesco V.I. Main Street Small Cap I 0.33

Principal SmallCap Growth I Instl 0.32

DWS Small Cap Core S 0.32

Small Cap Core Equity Composite 0.32

Fidelity Growth Company Fund 0.29

iShares US Pharmaceuticals ETF 0.26

PRIMECAP Odyssey Growth 0.25

Invesco RAFI US 1500 Small-Mid ETF 0.21

Eastern Shore Small Cap Equity 0.21

Nektar Therapeutics Market Status

Strong Buy: 2

Buy: 2

Hold: 3

Sell: 1

Strong Sell: 0

Nektar Therapeutics Fundamentals

Market Cap 2071.84 M

PB Ratio 23.9002

PE Ratio 0.0

Enterprise Value 1987.01 M

Total Assets 280.41 M

Volume 837535

Nektar Therapeutics Company Financials

Annual Revenue FY23:88260000 88.3M, FY22:92055000 92.1M, FY21:101907000 101.9M, FY20:152915000 152.9M, FY19:114617000 114.6M

Annual Profit FY23:55542000 55.5M, FY22:70420000 70.4M, FY21:77010000 77.0M, FY20:133438000 133.4M, FY19:93243000 93.2M

Annual Net worth FY23:-293665000 -293.7M, FY22:-368198000 -368.2M, FY21:-523837000 -523.8M, FY20:-444440000 -444.4M, FY19:-440667000 -440.7M

Quarterly Revenue Q3/2025:11790000 11.8M, Q2/2025:11175000 11.2M, Q1/2025:10460000 10.5M, Q3/2024:24124000 24.1M, Q2/2024:23489000 23.5M

Quarterly Profit Q3/2025:11594000 11.6M, Q2/2025:11175000 11.2M, Q1/2025:10460000 10.5M, Q3/2024:19689000 19.7M, Q2/2024:13749000 13.7M

Quarterly Net worth Q3/2025:-35522000 -35.5M, Q2/2025:-41593000 -41.6M, Q1/2025:-50882000 -50.9M, Q3/2024:-37057000 -37.1M, Q2/2024:-52363000 -52.4M

About Nektar Therapeutics & investment objective

Company Information Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Organisation Biotechnology

Employees 61

Industry Biotechnology

CEO Mr. Howard W. Robin

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Nektar Therapeutics FAQs

What is the share price of Nektar Therapeutics today?

The current share price of Nektar Therapeutics is $72.

Can I buy Nektar Therapeutics shares in India?

Yes, Indian investors can buy Nektar Therapeutics shares by opening an international trading and demat account with Motilal Oswal.

How to buy Nektar Therapeutics shares in India?

You can easily invest in Nektar Therapeutics shares from India by:

Can I buy fractional shares of Nektar Therapeutics?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Nektar Therapeutics?

Nektar Therapeutics has a market cap of $2071.84 M.

In which sector does Nektar Therapeutics belong?

Nektar Therapeutics operates in the Biotechnology sector.

What documents are required to invest in Nektar Therapeutics stocks?

To invest, you typically need:

What is the PE and PB ratio of Nektar Therapeutics?

The PE ratio of Nektar Therapeutics is N/A and the PB ratio is 23.90.